Table 1.
Patient characteristics of patients receiving neoadjuvant chemotherapy with methotrexate/vinblastine/adriamycin/cisplatin (MVAC), cisplatin/gemcitabine (CG), or other regimens.
| MVAC (n=22) | CG (n=24) | Other (n=15) | |
|---|---|---|---|
| Gender, n (%) | |||
| Female | 2 (9.1%) | 5 (20.8%) | 2 (13.3%) |
| Male | 20 (90.9%) | 19 (79.2%) | 13 (86.7%) |
| Age, median (IQR) † | 60.1 (52.7 – 68.1) | 68.6 (64.4 – 71.4) | 77.3 (69.0 – 82.6) |
| CCI, median (IQR) † | 4.0 (3.0 – 5.0) | 5.0 (4.0 – 6.0) | 6.0 (6.0 – 6.0) |
| ASA, n (%) | |||
| II | 2 (9.1%) | 2 (8.3%) | 1 (6.7%) |
| III | 18 (81.8%) | 14 (58.3%) | 7 (46.7%) |
| IV | 2 (9.1%) | 8 (33.3%) | 4 (26.7%) |
| Clinical T Stage, n (%) | |||
| ≤T2 | 18 (81.8%) | 19 (91.7%) | 7 (73.3%) |
| T3 | 1 (4.5%) | 2 (8.3%) | 3 (20.0%) |
| T4 | 2 (9.1%) | 0 (0.0%) | 1 (6.7%) |
| Clinical Grade, n (%) | |||
| II (Intermediate) | 1 (4.6%) | 0 (0.0%) | 1 (6.7%) |
| III (High) | 21 (95.4%) | 24 (100.0%) | 14 (93.3%) |
| Pathologic T Stage, n (%) | |||
| <pT1 | 9 (40.9%) | 9 (37.5%) | 5 (33.3%) |
| pT1 | 2 (9.1%) | 1 (4.2%) | 0 (0.0%) |
| pT2 | 5 (22.7%) | 4 (16.7%) | 1 (6.7%) |
| pT3 | 4 (18.2%) | 5 (20.8%) | 6 (40.0%) |
| pT4 | 2 (9.1%) | 5 (20.8%) | 3 (20.0%) |
| Nodal yield, n (IQR)† | 25 (20 – 41) | 27 (18 – 34) | 17 (6 – 20) |
| Pathologic node status, n (%) | |||
| NX or N0 | 23 (54.5%) | 16 (66.6%) | 14 (93.3%) |
| N1 | 4 (18.2%) | 2 (8.3%) | 1 (6.7%) |
| N2 | 5 (22.7%) | 5 (20.8%) | 0 (0.0%) |
| N3 | 1 (4.5%) | 1 (4.2%) | 0 (0.0%) |
| Positive surgical margins, n (%) | 1 (4.5%) | 6 (25.0%) | 3 (20.0%) |
†
p<0.05 from comparison testing; chi-square or fisher’s exact test used for categorical variables; student’s t-test or Wilcoxon test for non-parametric data used to compare continuous variables.